CORE ADANIPORTS+0.24% BIRET-0.24% BRIGADE-0.85% DLF-1.17% EMBASSY+1.10% GMRAIRPORT+0.00% GODREJPROP+0.19% IRB+3.46% LODHA-0.98% LT-1.76% MAHLIFE-1.64% MINDSPACE-1.39% NCC-0.64% OBEROIRLTY-0.14% PHOENIXLTD+0.11% PRESTIGE-0.22% SOBHA+0.95% as of 2026-08-26 16:27 UTC

The Annexure

Desk Healthcare Onesource Specialty Pharma Ltd

Onesource Specialty Pharma Ltd

BSE 544292 ONESOURCE INE013P01021
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals NIFTY 500

Filing rhythm · 60 trading days

14 filings · 6 material · busiest 2026-07-24

What it files

Filings

14 in the window

  1. 18 August 2026

    Credit Rating

    Credit Rating

    Intimation of Credit Rating issued by India Ratings and Research Private Limited vide press release dated August 17, 2026

    Company Update / Credit Rating View filing →

  2. 31 July 2026

    Concall Transcript

    Earnings Call Transcript

    Intimation of Transcript of Earnings call dated July 25, 2026

    Company Update / Earnings Call Transcript View filing →

  3. 27 July 2026

    Change in Management

    Change in Management

    Changes in Senior Management Personnel (SMP) of the Company - Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

    Company Update / Change in Management View filing →

  4. 24 July 2026

    Board Outcome

    Board Meeting Outcome for Intimation Of The Outcome Of The Board Meeting Dated July 24, 2026, For The Approval Of Unaudited Financial Results (Standalone And Consolidated) For The Quarter Ended June 30, 2026

    Outcome of the Board meeting dated July 24, 2026, for the approval of the unaudited financial results (Standalone and Consolidated) for the quarter ended June 30, 2026.

    Board Meeting / Outcome of Board Meeting View filing →

  5. 24 July 2026

    Change in Management

    Change in Management

    Changes in the Senior Managament Personnel of the Company-Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

    Company Update / Change in Management View filing →

  6. 24 July 2026

    Press Release

    Press Release / Media Release

    OneSource announces strong Q1FY27 results Revenue up 37% YoY and EBITDA up 39% YoY

    Company Update / Press Release / Media Release View filing →

  7. 24 July 2026

    ESOP Allotment

    Allotment of ESOP / ESPS

    Intimation of allotment of 2,900 ESOPs of Re.1 each under ONESOURCE ESOP 2021

    Company Update / Allotment of ESOP / ESPS View filing →

  8. 21 July 2026

    Analyst / Investor Meet

    Analyst / Investor Meet - Intimation

    Intimation of Earnings Call to be held on July 25, 2026.

    Company Update / Analyst / Investor Meet View filing →

  9. 20 July 2026

    Board Meeting

    Board Meeting Intimation for Approval Of The Unaudited Financial Results For The Quarter Ended June 30, 2026.

    Onesource Specialty Pharma Ltd has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 24/07/2026 ,inter alia, to consider and approve Unaudited financial ....

    Board Meeting / Board Meeting View filing →

  10. 14 July 2026

    General

    544292 - Onesource Specialty Pharma And Formycon AG Announce Strategic Manufacturing Partnership For Biosimilars

    OneSource Specialty Pharma and Formycon AG announce Strategic Manufacturing Partnership for Biosimilars

    Company Update / General View filing →

  11. 9 July 2026

    General

    Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulation, 2015

    We refer to the intimation made earlier today by Dr. Reddy's Laboratories (DRL) regarding delay in commercial supplies of Semaglutide. Refer intimation attached.

    Company Update / General View filing →

  12. 8 July 2026

    ESOP Allotment

    Allotment of ESOP / ESPS

    Allotment of 24,190 equity shares of Re. 1/- under ONESOURCE ESOP 2021 on July 08, 2026.

    Company Update / Allotment of ESOP / ESPS View filing →

  13. 2 July 2026

    General

    Completion Of US-FDA Inspection At Sterile Product Division (SPD) Facility At Bengaluru

    We wish to inform that a routine current Good Manufacturing (cGMP) inspection was conducted by the United States Food and Drug Administration (USFDA) at the Sterile Product Division facility ....

    Company Update / General View filing →

  14. 24 June 2026

    Trading Window

    Closure of Trading Window

    Intimation of closure of Trading window for declaration of unaudited financial results for the quarter ended June 30, 2026.

    Insider Trading / SAST / Closure of Trading Window View filing →